COMPOSITION AND METHOD FOR TREATING ACUTE RESPIRATORY TRACT INFECTIONS
A composition consists of an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”), an effective amount of a synthetic neutral non-fucosylated HMO, and one or more excipients acceptable for enteral administration to a non-infant human. In some embodiments, the synthetic neutral fucosylated HMO is 2′-fucosyllactose and the synthetic neutral non-fucosylated HMO is selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”). In certain embodiments, the mass ratio of 2′-FL to the selected LNnT or LNT is about 1.5 to about 4.5. In one embodiment, the synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). In certain embodiments, the one or more excipients acceptable for enteral administration to a human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. In various embodiments, the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet.
1 . A composition consisting of:
an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”) consisting of 2′-fucosyllactose (“2′-FL”);
an effective amount of at least one synthetic neutral non-fucosylated HMO selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”); and
one or more excipients acceptable for enteral administration to a human.
2 . (canceled)
3 . The composition of claim 1 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5.
4 . The composition of claim 1 , wherein the synthetic neutral non-fucosylated HMO consists of lacto-N-neotetraose (“LNnT”).
5 . The composition of claim 1 , wherein the one or more excipients acceptable for enteral administration to the human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof.
6 . The composition of claim 1 , wherein the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet.
7 . A composition consisting essentially of:
an effective amount of synthetic 2′-fucosyllactose (“2′-FL”) and at least one synthetic neutral human milk oligosaccharide (“HMO”) selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”).
8 . The composition of claim 7 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5.
9 . The composition of claim 7 , wherein the at least one synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”).
10 . A composition consisting of:
an effective amount of synthetic 2′-fucosyllactose (“2′-FL”) and at least one synthetic neutral human milk oligosaccharide (“HMO”) selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”).
11 . The composition of claim 10 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5.
12 . The composition of claim 11 , wherein the at least one synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”).